AUG 09, 2018 7:00 AM PDT

3D Cell Cultures and Tissue Clearing: A High Content Confocal Platform for the Complete 3D Characterization of Advanced Cell Models

Sponsored by: Thermo Fisher Scientific
  • Chief Executive Officer - Visikol Inc.
      Michael Johnson, PhD is a 2017 and 2019 Forbes 30 Under 30 honoree and the CEO and Co-Founder of Visikol Inc., which is a bio-imaging company that spun out of Rutgers University in 2016 and that Michael founded along with his fellow PhD candidate Thomas Villani and colleague Nick Crider. Michael has a diverse background with experiences in both the technical and business considerations of running a biotech business. Following his undergraduate degree in biology at Muhlenberg College, Michael spent three years in various roles at Johnson & Johnson while concurrently pursuing a PhD in applied microbiology at Rutgers University. Michael's research background has focused on a wide-range of projects from remote sensing research with NASA to building light sheet microscopes and producing biofuels. Prior to launching Visikol, Michael worked on several other biotech-based entrepreneurial pursuits and is very passionate about translating cutting edge research into life-changing commercial technologies.


    DATE: August 9, 2018
    TIME: 7:00AM PDT

    With the advent of cost-effective culturing approaches, 3D cell culture models (3D-CCMs) have been rapidly adopted for drug discovery since they provide a more physiologically relevant micro-environment; showing improved predictive utility for assessing drug efficacy and/or toxicity when compared to traditional 2D monolayer models. High-content analysis/screening (HCA/HCS) also plays a major role in drug screening, but one of the unique challenges of evaluating 3D-CCMs (i.e. spheroids, organoids, micro-tissues, organs-on-a-chip) is their opacity and thickness that limit optical imaging to only the outermost layers (~20=30 microns). Since the outermost cells are exposed to different physiological test conditions (oxygen, nutrients, media exchange, drug dosing), current image-based approaches induce a bias in the results since the outer layer of cells are found in a significantly different micro-environment than the interior. This shortcoming is particularly problematic when ascertaining the relative effectiveness of current therapeutic agents (e.g. immunoglobulin-based therapeutics, anti-proliferatives) since their effects are likely to be localized or concentrated to the surface while their efficacy within the interior are obfuscated and not fully resolved. Visikol™ has shown that through the addition of high content confocal microscopy with the Thermo Scientific™ CellInsight™ CX7 LZR High-Content Analysis Platform and the Invitrogen™ CytoVista™ 3D Cell Culture Clearing Reagent that the entire population of cells within 3D-CCMs can be characterized.

    Learning Objectives:

    • Benefits of imaging 3D Cell Cultures 
    • Practical considerations for buying a High-Content Analysis Platform

    Show Resources
    AUG 09, 2018 7:00 AM PDT

    3D Cell Cultures and Tissue Clearing: A High Content Confocal Platform for the Complete 3D Characterization of Advanced Cell Models

    Sponsored by: Thermo Fisher Scientific


    Cell Biology

    Cell Culture

    Cancer Research

    Molecular Biology



    Cancer Therapeutics

    Cell Signaling / Transduction


    Drug Discovery


    Gene Expression

    Assay Development


    Cancer Diagnostics


    North America53%



    South America4%



    Registration Source

    Website Visitors62%

    WAVE Newsletter Promotion20%

    Email Promotions14%

    Social Media Promotions2%

    Website Banners1%

    Trending Newsletter Promotion1%


    Job Title

    Research Scientist18%





    Medical Laboratory Technician8%

    Post Doc8%

    Facility/Department Manager7%

    Clinical Laboratory Scientist3%

    Medical Doctor/Specialist3%


    Lab Management2%




    Academic Institution21%

    Biotech Company14%

    Research Institute13%


    Life Science Company6%

    Medical School5%


    Clinical Laboratory4%

    Pharmaceutical Company4%

    Medical Center3%

    Industrial Company2%

    Non-Profit Organization2%

    Contract Research Organization (Cro)2%



    Show Resources
    Show Resources
    • See more
    Connect with us